Particularly, AXL mediates resistance to PI3Kα inhibition through activation of EGFR/PKC/mTOR cascade in head and neck (H&N) carcinomas as well in ESCC (105). This evidence concerns the gene AXL and esophageal squamous cell carcinoma.